CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2018-04-18
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly
given in combination with rituximab, can help to control the disease in patients with ALL.
The safety of the study drug(s) will also be studied.